Shanta Biotech expects to conduct clinical trials on these substances targeting non-small-cell lung, pancreatic, colon, and breast cancer, respectively. According to an analyst, the human trials on monoclonal antibodies will strengthen Shanta's oncology portfolio.
But if a product is finally brought to the market, it will bring a drop in prices in the same segment. Shanta's corporate strategy has been to bring products into the market at a price lower than the existing market price, as was seen with the Hepatitis B vaccine and interferon.
The latter was launched at a price 40 per cent less than its imported counterparts.
